Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Objective:
Osteosarcoma
is the most common primary malignant bone tumor. However, the survival of patients with
osteosarcoma
has remained unchanged during the past 30 years, owing to a lack of efficient therapeutic targets.
Methods:
We constructed a kinome-targeting CRISPR-Cas9 library containing 507 kinases and 100 nontargeting controls and screened the potential kinase targets in
osteosarcoma
. The CRISPR screening sequencing data were analyzed with the Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) Python package. The functional data were applied in the 143B cell line through lenti-CRISPR-mediated gene knockout. The clinical significance of kinases in the survival of patients with
osteosarcoma
was analyzed in the R2: Genomics Analysis and Visualization Platform.
Results:
We identified 53 potential kinase targets in
osteosarcoma
. Among these targets, we analyzed 3 kinases, TRRAP,
PKMYT1
, and TP53RK, to validate their oncogenic functions in
osteosarcoma
.
PKMYT1
and TP53RK showed higher expression in
osteosarcoma
than in normal bone tissue, whereas TRRAP showed no significant difference. High expression of all 3 kinases was associated with relatively poor prognosis in patients with
osteosarcoma
.
Conclusions:
Our results not only offer potential therapeutic kinase targets in
osteosarcoma
but also provide a paradigm for functional genetic screening by using a CRISPR-Cas9 library, including target design, library construction, screening workflow, data analysis, and functional validation. This method may also be useful in potentially accelerating drug discovery for other cancer types.
...
PMID:Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library. 3294 6